Inclusion Criteria:

          1. 18 to 70 Years Old, female;

          2. Expected survival > 12 weeks;

          3. Clinical performance status of ECOG score 0-2;

          4. Patients who have previously been treated with second- line or more lines of standard
             treatment are not effective (No remission or recurrence after remission);

          5. At least one measurable tumor foci according to RECIST standard 1.1 ;

          6. Positive Mesothelin expression in tumor tissues;

          7. Creatinine ≤ 1.5×ULN;

          8. ALT and AST ≤ 3×ULN;

          9. Total bilirubin ≤ 2×ULN;

         10. Hemoglobin≥90g/L;

         11. Absolute counting of neutrophils≥1000uL ;

         12. Absolute counting of lymphocytes>0.7×10^9/L;

         13. Counting of Platelet≥75000/uL;

         14. The venous access required for collection can be established without contraindications
             for leukocyte collection;

         15. Able to understand and sign the Informed Consent Document.

        Exclusion Criteria:

          1. Accompanied by other uncontrolled malignant tumors;

          2. Active hepatitis B, hepatitis C, syphilis, HIV infection;

          3. Suffering severe cardiovascular or respiratory disease;

          4. Any other diseases could affect the outcome of this trial;

          5. Any affairs could affect the safety of the subjects or outcome of this trial;

          6. Pregnant or lactating women, or patients who plan to be pregnancy during or after
             treatment;

          7. There are active or uncontrollable infections (except simple urinary tract infections
             or upper respiratory tract infections) that require systemic therapy 14 days or 14
             days prior to assignment;

          8. Patients who are accounted by researchers to be not appropriate for this test;

          9. Received CAR-T treatment or other gene therapies before assignment;

         10. Subject suffering disease affects the understanding of informed consent or comply with
             study protocol.